These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 23548793

  • 1. A novel nuclear factor κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates puromycin aminonucleoside-induced nephrosis in mice.
    Shimo T, Adachi Y, Yamanouchi S, Tsuji S, Kimata T, Umezawa K, Okigaki M, Takaya J, Ikehara S, Kaneko K.
    Am J Nephrol; 2013; 37(4):302-9. PubMed ID: 23548793
    [Abstract] [Full Text] [Related]

  • 2. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
    Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K.
    Clin Cancer Res; 2005 Feb 01; 11(3):1287-93. PubMed ID: 15709200
    [Abstract] [Full Text] [Related]

  • 3. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Ueki S, Yamashita K, Aoyagi T, Haga S, Suzuki T, Itoh T, Taniguchi M, Shimamura T, Furukawa H, Ozaki M, Umezawa K, Todo S.
    Transplantation; 2006 Dec 27; 82(12):1720-7. PubMed ID: 17198266
    [Abstract] [Full Text] [Related]

  • 4. Dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-kappaB inhibitor, inhibits allergic inflammation and airway remodelling in murine models of asthma.
    Shimizu K, Konno S, Ozaki M, Umezawa K, Yamashita K, Todo S, Nishimura M.
    Clin Exp Allergy; 2012 Aug 27; 42(8):1273-81. PubMed ID: 22805475
    [Abstract] [Full Text] [Related]

  • 5. Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells.
    Meng Z, Mitsutake N, Nakashima M, Starenki D, Matsuse M, Takakura S, Namba H, Saenko V, Umezawa K, Ohtsuru A, Yamashita S.
    Endocrinology; 2008 Nov 27; 149(11):5357-65. PubMed ID: 18653704
    [Abstract] [Full Text] [Related]

  • 6. Pleiotropic potential of dehydroxymethylepoxyquinomicin for NF-κB suppression via reactive oxygen species and unfolded protein response.
    Nakajima S, Kato H, Gu L, Takahashi S, Johno H, Umezawa K, Kitamura M.
    J Immunol; 2013 Jun 15; 190(12):6559-69. PubMed ID: 23690471
    [Abstract] [Full Text] [Related]

  • 7. Adrenomedullin ameliorates podocyte injury induced by puromycin aminonucleoside in vitro and in vivo through modulation of Rho GTPases.
    Dong N, Meng L, Xue R, Yu M, Zhao Z, Liu X.
    Int Urol Nephrol; 2017 Aug 15; 49(8):1489-1506. PubMed ID: 28528353
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance.
    Watanabe M, Yamashita K, Kamachi H, Kuraya D, Koshizuka Y, Shibasaki S, Asahi Y, Ono H, Emoto S, Ogura M, Yoshida T, Ozaki M, Umezawa K, Matsushita M, Todo S.
    Transplantation; 2013 Sep 15; 96(5):454-62. PubMed ID: 23860082
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: I. HMGB1 suppression by DHMEQ prevents early islet graft damage.
    Kuraya D, Watanabe M, Koshizuka Y, Ogura M, Yoshida T, Asahi Y, Kamachi H, Nakamura T, Harashima H, Ozaki M, Umezawa K, Matsushita M, Yamashita K, Todo S.
    Transplantation; 2013 Sep 15; 96(5):445-53. PubMed ID: 23900151
    [Abstract] [Full Text] [Related]

  • 10. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
    Nishimura D, Ishikawa H, Matsumoto K, Shibata H, Motoyoshi Y, Fukuta M, Kawashimo H, Goto T, Taura N, Ichikawa T, Hamasaki K, Nakao K, Umezawa K, Eguchi K.
    Int J Oncol; 2006 Sep 15; 29(3):713-9. PubMed ID: 16865289
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling.
    Shibata S, Nagase M, Fujita T.
    J Am Soc Nephrol; 2006 Mar 15; 17(3):754-64. PubMed ID: 16452496
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
    Kuroda K, Horiguchi Y, Nakashima J, Kikuchi E, Kanao K, Miyajima A, Ohigashi T, Umezawa K, Murai M.
    Clin Cancer Res; 2005 Aug 01; 11(15):5590-4. PubMed ID: 16061877
    [Abstract] [Full Text] [Related]

  • 19. Immunomodulatory effect of nuclear factor-κB inhibition by dehydroxymethylepoxyquinomicin in combination with donor-specific blood transfusion.
    Goto R, Yamashita K, Aoyagi T, Ueki S, Uno M, Oura T, Kobayashi N, Igarashi R, Shibasaki S, Wakayama K, Hirokata G, Shibata T, Zaitsu M, Umezawa K, Ozaki M, Todo S.
    Transplantation; 2012 Apr 27; 93(8):777-86. PubMed ID: 22357176
    [Abstract] [Full Text] [Related]

  • 20. Nicorandil protects podocytes via modulation of antioxidative capacity in acute puromycin aminonucleoside-induced nephrosis in rats.
    Yamanaka M, Tamura Y, Kuribayashi-Okuma E, Uchida S, Shibata S.
    Am J Physiol Renal Physiol; 2023 Feb 01; 324(2):F168-F178. PubMed ID: 36454699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.